Dr. Reddy's and RDIF commence clinical trials for Sputnik V vaccine in India

▴ Dr. Reddy's and RDIF commence clinical trials for Sputnik V vaccine in India
This will be a multicenter and randomized controlled study, which will include a safety and immunogenicity study.

Reddy’s Laboratories Ltd. and the Russian Direct Investment Fund (RDIF) announced today that they have commenced adaptive phase 2/3 clinical trials for Sputnik V vaccine in India after receiving the necessary clearance from the Central Drugs Laboratory, Kasauli, India. This will be a multicenter and randomized controlled study, which will include a safety and immunogenicity study.

The clinical trials are being conducted by JSS Medical Research as a clinical research partner. Further, Dr. Reddy’s has partnered with the Biotechnology Industry Research Assistance Council (BIRAC), Department of Biotechnology (DBT) for advisory support and to use BIRAC’s clinical trial centers for the vaccine.

Recently, RDIF announced the second interim analysis of clinical trial data, which showed 91.4% efficacy for the vaccine on day 28 after the first dose; vaccine efficacy over 95% 42 days after the first dose. Currently, 40,000 volunteers are taking part in Phase III of Sputnik V clinical trials, out of which over 22,000 have been vaccinated with the first dose of the vaccine and more than 19,000 – with both the first and second doses of the vaccine.

G V Prasad, Co-chairman and Managing Director, Dr. Reddy’s Laboratories said, “This is another significant step as we continue to collaborate with multiple entities along with the government bodies to fast-track the process for launching the vaccine in India. We are working towards making the vaccine available with a combination of import and indigenous production model.”

In September 2020, Dr. Reddy’s and RDIF entered into a partnership to conduct clinical trials of the Sputnik V vaccine and the rights for distribution of the first 100 million doses in India.

On August 11, 2020, the Sputnik V vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and became the World’s first registered vaccine against COVID-19 based on the human adenoviral vector platform.

Tags : #LatestPharmaNewsDec2 #LatestDrReddysNewsDec2 #TreatmentforCOVID19 #SputnikVVaccine

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Deworming in Children: A Crucial Step Towards Healthy GrowthFebruary 07, 2025
AI-powered blue-collar hiring platform Vahan.ai secures investment from APAC HR services leader Persol Group amid booming gig economy in India; plans to develop AI recruitment technology to support 8 major Indian languages February 07, 2025
Scars That Never Heal: The Painful Reality of Female Genital MutilationFebruary 06, 2025
Maharashtra’s Healthcare Betrayal: Why Are Crucial Funds Going Unused?February 06, 2025
1vision, 1 mission: Avaada Foundation’s CSR initiatives are powering communities and delivering sustainable progress across 5 key focus areasFebruary 06, 2025
Top 5 Technology Brands that are Transforming the Cancer Care Journeys for Hospitals and PatientsFebruary 06, 2025
Women's Wellness brand NUA Raises Rs 35 Crore in Pre-Series C led by Mirabilis Investment TrustFebruary 06, 2025
8 Effective Ways to Minimize Postpartum ComplicationsFebruary 06, 2025
Does Where You Live Decide Your Fate? The Urban-Rural Breast Cancer Divide in IndiaFebruary 06, 2025
Nepal leads the world with largest pictorial health warnings on all tobacco productsFebruary 05, 2025
Fleetguard Filters Private Limited Recognized for Excellence in CSR at Navabharat’s 4th CSR ConclaveFebruary 05, 2025
Six new regions of the Russian Federation are set to connect to Moscow's AI medical services platform, MosMedAIFebruary 04, 2025
Six new regions of the Russian Federation are set to connect to Moscow's AI medical services platform, MosMedAIFebruary 04, 2025
Ashok Leyland Reinforces ESG Commitment, Ranked No. 1 Globally in Sustainalytics’ RatingsFebruary 04, 2025
Calcium Supplements: Do You Really Need Them?February 04, 2025
Digital Diagnostics Doubles Its Foreign Publication Count in 2024February 04, 2025
World Cancer Day quotesFebruary 04, 2025
India can take a big leap in Cancer Care with Improved access to treatment and People-centered Approach: ExpertsFebruary 04, 2025
Lilly India appoints Winselow Tucker as the President and General ManagerFebruary 04, 2025
Driving Excellence in Clinical Research: ISCR's 18th Annual Conference Highlights Innovation, Technology, and Patient-CentricityFebruary 04, 2025